SEC Form 3 · accession 0001209191-19-008215

Harpoon Therapeutics, Inc. · HARP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Feb 7, 2019

Accepted (ET)

Feb 7, 2019 · 6:23 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001708493

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	52,669	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1	$0.60	holding	—	—	—	—	Apr 6, 2026	Common Stock	32,536	—	D
Employee Stock Option (right to buy)^F2	$0.60	holding	—	—	—	—	Jan 13, 2027	Common Stock	61,006	—	D
Employee Stock Option (right to buy)^F3	$1.63	holding	—	—	—	—	Jun 22, 2027	Common Stock	20,538	—	D
Employee Stock Option (right to buy)^F4	$2.12	holding	—	—	—	—	Nov 16, 2018	Common Stock	95,170	—	D

F1The stock option vested and became exercisable as to 25% of the shares subject to the option on April 6, 2017, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F2The stock option vested and became exercisable as to 25% of the shares subject to the option on May 24, 2017, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F3The stock options vested and became exercisable as to 1/48th of the total number of shares on July 16, 2018, then an additional 1/48th vested on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F4The stock option vests and becomes exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.